Novel and Personalized Treatment Concepts in Gynecologic Cancer—2nd Edition

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy in Clinical Medicine".

Deadline for manuscript submissions: 10 March 2026 | Viewed by 1616

Special Issue Editors


E-Mail Website
Guest Editor
Division of General Gynaecology and Gynaecological Oncology, Medical University of Vienna—Vienna General Hospital, 1090 Vienna, Austria
Interests: gynecologic oncology; tumor biology of ovarian cancer; medical treatment for cervical cancer precursor lesions
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Comprehensive Cancer Center-Gynecologic Cancer Unit, Medical University of Vienna, 1090 Vienna, Austria
Interests: gynecologic oncology; tumor biology of ovarian cancer; medical treatment for cervical cancer precursor lesions
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The field of gynecologic oncology has significantly evolved over the last years. The introduction of molecular analysis has changed the way we classify endometrial and epithelial ovarian cancers. Moreover, surgical treatment concepts have developed due to the introduction of the sentinel lymph node technique, allowing us to spare patients from unnecessary morbidities. Finally, predictive biomarkers such as BRCA mutations, homologous recombination deficiency and microsatellite instability have revolutionized the treatment of a variety of gynecologic malignancies.

In the precision medicine era, further understanding of cancer genomics and the identification of predictive biomarkers are essential to achieve better health outcomes for women with gynecologic cancer.

In this Special Issue, we aim to cover highly innovative findings and concepts within the field of gynecologic oncology, ranging from diagnostics to therapeutic approaches, that could improve the way we diagnose, classify and/or treat gynecologic malignancies.

Dr. Stephan Polterauer
Dr. Christoph Grimm
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ovarian cancer
  • endometrial cancer
  • vulvar cancer
  • cervical cancer
  • homologous recombination
  • targeted therapy
  • DNA damage repair
  • biomarkers
  • imaging
  • individualized treatment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 291 KB  
Review
Novel Treatment Concepts for Cervical Cancer—Moving Towards Personalized Therapy
by Melina Danisch, Magdalena Postl, Thomas Bartl, Christoph Grimm, Alina Sturdza, Nicole Concin and Stephan Polterauer
J. Pers. Med. 2025, 15(11), 523; https://doi.org/10.3390/jpm15110523 - 1 Nov 2025
Viewed by 1145
Abstract
In recent years, several randomized controlled trials have been published regarding cervical cancer therapy and significantly changed the treatment landscape. Recent advances have improved the treatment options and allow personalized treatment concepts with escalation of treatment in high-risk disease and de-escalation with reduction [...] Read more.
In recent years, several randomized controlled trials have been published regarding cervical cancer therapy and significantly changed the treatment landscape. Recent advances have improved the treatment options and allow personalized treatment concepts with escalation of treatment in high-risk disease and de-escalation with reduction in morbidity in selected low-risk patients. This review aims to provide a comprehensive analysis of the latest landmark studies that are poised to significantly influence clinical practice. Personalized treatment concepts with careful patient selection allow de-escalation in the surgical treatment of cervical cancer. In low-risk cervical cancer patients (lesions of ≤2 cm with limited stromal invasion), simple hysterectomy (SH) was non-inferior to radical hysterectomy in terms of 3-year incidence of pelvic recurrence and was associated with a lower risk of urinary incontinence or retention and improved sexual health and quality of life. Furthermore, sentinel lymphadenectomy is constantly replacing systematic pelvic lymphadenectomy in patients with low-risk cervical cancer. In addition, further studies are necessary to clarify the role of postoperative therapy for patients with intermediate-risk cervical cancer. Starting in 2008, the EMBRACE studies assess the role of Image guided adaptive brachytherapy (IGABT) in LACC in addition to modern external beam radiotherapy concurrent to chemotherapy. The publication of the results of the EMBRACE I prospective study established MRI guided IGABT as state-of-the-art brachytherapy for LACC. EMBRACE II and additional prospective studies emerging from this consortium will address important questions in modern radiotherapy for LACC. Immune checkpoint inhibitors (CPIs) have been evaluated across various clinical settings and are expected to be utilized in numerous scenarios due to several positive randomized trials. Particularly, the combination of platinum-based chemotherapy and pembrolizumab, with or without bevacizumab, has been established as the new standard treatment for primary metastatic or recurrent PD-L1 positive high-risk cervical cancer. In locally advanced cervical cancer, two new treatment escalation regimens—neoadjuvant chemotherapy and adjuvant CPI therapy—have been evaluated in addition to chemoradiation. Furthermore, antibody-drug conjugates, such as tisotumab-vedotin, represent a promising future therapeutic option for recurrent cervical cancer. Full article
Back to TopTop